Free Trial

Noble Financial Upgrades Zomedica (NYSEAMERICAN:ZOM) to "Strong-Buy"

Zomedica logo with Medical background

Zomedica (NYSEAMERICAN:ZOM - Get Free Report) was upgraded by Noble Financial to a "strong-buy" rating in a research note issued on Monday,Zacks.com reports.

Zomedica Stock Up 17.3 %

Shares of ZOM stock traded up $0.02 during trading on Monday, hitting $0.14. The company's stock had a trading volume of 25,571,575 shares, compared to its average volume of 4,687,302. The firm has a market cap of $140.72 million, a PE ratio of -2.05 and a beta of 1.06. Zomedica has a 52 week low of $0.12 and a 52 week high of $0.23.

Institutional Investors Weigh In On Zomedica

An institutional investor recently raised its position in Zomedica stock. Virtu Financial LLC increased its holdings in Zomedica Corp. (NYSEAMERICAN:ZOM - Free Report) by 1,585.0% during the first quarter, according to its most recent disclosure with the SEC. The institutional investor owned 168,773 shares of the company's stock after buying an additional 158,757 shares during the period. Virtu Financial LLC's holdings in Zomedica were worth $25,000 as of its most recent SEC filing. Hedge funds and other institutional investors own 8.95% of the company's stock.

Zomedica Company Profile

(Get Free Report)

Zomedica Corp., a veterinary health company, focuses on the unmet needs of clinical veterinarians by developing products for companion animals. The company offers diagnostic products comprising TRUFORMA Bulk Acoustic Wave point of care diagnostic platform; TRUVIEW, a digital cystoscopy platform that offers automated slide preparation within the instrument; and VetGuardian, a zero-touch vital signs remote monitoring system.

Further Reading

Should You Invest $1,000 in Zomedica Right Now?

Before you consider Zomedica, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Zomedica wasn't on the list.

While Zomedica currently has a Strong Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

10 "Recession Proof" Stocks That Will Thrive in Any Market Cover

Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

5 Stocks to BUY NOW in May 2025
3 Stocks Offering Rare Generational Buying Opportunities
Make Your Money Work Harder: The Power of Dividend Investing

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines